With a Leaner Structure and Maturing Technologies, Marina Looks to Rebuild | GenomeWeb

With a portfolio of more mature technologies and increased interest in RNAi from the investment and pharmaceutical communities alike, Marina Biotech expects to rebuild itself as a leaner company with a greater focus on drug discovery, the struggling company’s top official said this week.

According to Marina President and CEO Michael French, the firm’s strategy of buying up attractive RNAi technologies put it under a financial burden it proved incapable of supporting, which contributed to its virtual shutdown last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.